FIT4KiD

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

4 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

The purpose of this NIH-funded placebo-controlled clinical trial is to determine how well ferric citrate will lower FGF23, correct anemia and iron levels in the blood, and maintain normal levels of phosphate in children with CKD. Chronic Kidney Disease (CKD) is a condition in which the kidney function is decreased. Fibroblast Growth Factor 23 (FGF23) is a hormone that regulates blood phosphate levels. High FGF23 levels are linked with worsening of kidney, bone & heart health. Ferric Citrate is an oral medication that decreases the absorption of dietary phosphate by the gut, lowers FGF23 levels and raises iron stores in the body. Ferric Citrate is approved in adults with CKD but has not yet been studied in children.

For more information visit the FIT4KID website.

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at chop_fit4kid [at] chop.edu or 267-425-4541.

Eligibility & Criteria

IRB #:
21-018701
Official Title:
Ferric Citrate and Chronic Kidney Disease in Children
Study Phase:
Phase II
Eligible Age Range:
6 - 17 Years
Gender:
All
Study Categories:

Visit Criteria

Eligible participants will be randomized to take ferric citrate or placebo with meals for about one year.
The study will include 6 in-person study visits, 3 virtual visits and 6 telephone calls. Participants will be asked to give blood and urine samples, and to complete surveys.